Post marketing study of sofosbuvir and ribavirin for hepatitis C virus genotype 2 infection

Post marketing study of sofosbuvir and ribavirin for hepatitis C virus genotype 2 infection - Post marketing study of sofosbuvir and ribavirin for hepatitis C virus genotype 2 infection

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000023269

Enrollment

100

Registered

2016-07-21

Start date

2015-07-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C virus infection

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with genotype 2 HCV infection

Exclusion criteria

Exclusion criteria: 1)pregnant woman 2)decompensated cirrhosis 3)severe renal function(<eGFR30)

Design outcomes

Primary

Measure	Time frame
Sustained virological response at 12 weeks after the end of treatment	—

Countries

Japan

Contacts

Public ContactHideyuki Tamai

Wakayama Medical University Second department of internal medicine

tamahide@wakayama-med.ac.jp073-447-2300

Outcome results